This announcement is a separate document:
AstraZeneca | 6-K: Voydeya Approved in the Us as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Haemolysis in Adults with the Rare Disease PNH
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.